Read More Pharma Industry News A small pancreatic cancer study just sent RenovoRx shares soaring. The biggest test is still ahead RenovoRx shares surge after TAMP data show 51% targeted gemcitabine extraction. See why TIGeR-PaC survival results remain the key catalyst. bySoujanya RaviAugust 27, 2026